Valuation: Cerus Corporation

Market Cap 430M 386M 353M 322M 606M 40.44B 626M 4.25B 1.69B 21.58B 1.61B 1.58B 68.11B P/E 2026 *
-73.5x
P/E 2027 * -
Enterprise Value 435M 390M 357M 326M 613M 40.91B 633M 4.3B 1.71B 21.83B 1.63B 1.6B 68.9B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.58x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day-5.16%
1 week-11.40%
Current month-11.40%
1 month-13.68%
3 months-12.93%
6 months-22.01%
Current year-1.94%
1 week 2.01
Extreme 2.01
2.52
1 month 2.01
Extreme 2.01
2.52
Current year 1.62
Extreme 1.62
3.47
1 year 1.47
Extreme 1.47
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
7.98
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-30,000 0.0150%
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
-5.16%-11.40%+43.26%+18.82% 430M
-3.23%+3.51%-12.02%+15.72% 197B
-2.75%+11.65%-7.90%+17.71% 128B
-2.90%+5.45%+13.04%+38.65% 128B
+0.96%+8.75%-38.73%+11.23% 99B
-1.80%+0.82%-7.41%+69.42% 64.82B
-0.78%+7.07%+19.44%-18.22% 58.17B
+0.79%+22.65%-5.28%+59.81% 52.84B
-6.98%-14.56%-12.60%+42.69% 50.69B
-2.36%+4.32%+2.44%-8.53% 37.23B
Average -2.42%+4.51%-0.58%+24.73% 81.58B
Weighted average by Cap. -2.24%+6.12%-6.98%+24.37%

Financials

2026 *2027 *
Net sales 242M 217M 199M 181M 342M 22.79B 353M 2.4B 955M 12.16B 910M 891M 38.39B 264M 237M 216M 197M 372M 24.8B 384M 2.61B 1.04B 13.23B 990M 969M 41.77B
Net income -7.3M -6.55M -5.99M -5.47M -10.3M -687M -10.62M -72.17M -28.78M -366M -27.42M -26.83M -1.16B -3.49M -3.13M -2.86M -2.61M -4.92M -328M -5.08M -34.48M -13.75M -175M -13.1M -12.82M -553M
Net Debt 5M 4.48M 4.1M 3.74M 7.05M 470M 7.27M 49.4M 19.7M 251M 18.77M 18.37M 792M -13M -11.66M -10.66M -9.73M -18.33M -1.22B -18.9M -128M -51.22M -652M -48.8M -47.75M -2.06B
Projected Income Statement - Annual - Cerus Corporation
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-11-06 US$2.020 -5.16% 2,069,440
26-11-05 US$2.130 -11.80% 2,453,711
26-11-04 US$2.415 +3.21% 2,512,557
26-11-03 US$2.340 -0.85% 3,497,692
26-11-02 US$2.360 +3.51% 3,984,992
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cerus Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.020USD
Average target price
5.125USD
Spread / Average Target
+153.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerus Corporation
  1. Stock Market
  2. Stocks
  3. CERS Stock